<SEC-DOCUMENT>0001513162-20-000189.txt : 20200902
<SEC-HEADER>0001513162-20-000189.hdr.sgml : 20200902
<ACCEPTANCE-DATETIME>20200901203011
ACCESSION NUMBER:		0001513162-20-000189
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200827
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200902
DATE AS OF CHANGE:		20200901

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		201155511

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body vlink=#954f72 link=#0563c1 lang=EN-US> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:14pt; LINE-HEIGHT:174%">UNITED STATES<a name=Form_8_K></font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:14pt; LINE-HEIGHT:174%">SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">WASHINGTON, DC 20549</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">_______________</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:16pt; LINE-HEIGHT:174%">FORM 8-K</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">CURRENT REPORT</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; page:WordSection1' align=center><b><font style=FONT-SIZE:12pt>Pursuant to Section 13 or 15(d) of the</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">Securities Exchange Act of 1934</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:6pt 0in 0pt; page:WordSection1' align=center><font style=FONT-SIZE:11pt>Date of Report (Date of earliest event reported):<b>&nbsp;&nbsp;August 27, 2020</b></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; page:WordSection1' align=center><b><font style=FONT-SIZE:20pt>BIOMERICA, INC.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 12pt; page:WordSection1' align=center>(Exact name of registrant as specified in its charter)</p> <div style=page:WordSection1 align=center> <table width=696 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>Delaware</font></b></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>001-37863</font></b></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>95-2645573</font></b></p></td></tr> <tr style=HEIGHT:26pt> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(State or Other Jurisdiction</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>of Incorporation)</p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(Commission</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>File Number)</p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(IRS Employer</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>Identification No.)</p></td></tr></table></div> <div style=page:WordSection1 align=center>&nbsp;</div> <div style=page:WordSection1 align=center> <table width=696 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=89 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:67pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'>&nbsp;</p></td> <td width=517 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:388pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>17571 Von Karman Ave. Irvine, California</font></b></p></td> <td width=89 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:67pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>92614</font></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=89 style="HEIGHT:14pt; WIDTH:67pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'>&nbsp;</p></td> <td width=517 style="HEIGHT:14pt; WIDTH:388pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style=COLOR:black>(Address of Principal Executive Offices)</font></p></td> <td width=89 style="HEIGHT:14pt; WIDTH:67pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style=COLOR:black>(Zip Code)</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; page:WordSection1' align=center>Registrant's telephone number, including area code:&nbsp; <b>(949) 645-2111</b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style=COLOR:black>Not Applicable</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center>(Former name or former address if changed since last report)</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:3pt 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>Securities registered pursuant to Section 12(b) of the Act:</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <div style=page:WordSection1 align=center> <table width=683 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Title of each class</font></u></b></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Trading Symbol</font></u></b></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">Common Stock, par value $0.08</font></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">BMRA</font></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1' align=left>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font> </p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1' align=left>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font></p><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'><br clear=all></font> <div style=page:WordSection2> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 12pt' align=center>1<b> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> <p></b> <p class=MsoNormal style=MARGIN:0in><b><font style=FONT-SIZE:10pt>Item 5.02&nbsp; </font></b><b><font style="FONT-SIZE:10pt; COLOR:black">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain&nbsp; Officers; Compensatory Arrangements of Certain Officers.</font></b><b><font style=FONT-SIZE:10pt></font></b></p> <p style=MARGIN:0in><font size=3>&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>In December 2019, Ms. Janet Moore, age 69, informed Biomerica, Inc. (the &#147;Company&#148;), about her intention to retire from the position of Chief Financial Officer (&#147;CFO&#148;) of the Company at some point in the future once a suitable replacement could be found. On July 13, 2020 the Board of Directors of the Company unanimously approved hiring Mr. Steve Sloan.&nbsp; On August 27, 2020 the Board of Directors officially appointed and approved Mr. Sloan to serve as CFO, effective September 3, 2020. As such, Ms. Moore will resign her position as CFO effective September 3, 2020.</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>Ms. Moore&#146;s retirement was not as a result of any disagreements with the Company, including on any matters related to its operations, policies or practices.&nbsp; Ms. Moore will continue working for Biomerica during a transition period.</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>The Board of Directors of the Company also voted that Mr. Sloan will receive an option grant of 50,000 shares of our common stock which option grant vests one-quarter on July 13, 2021 and one-quarter on each yearly anniversary thereafter of the grant.&nbsp; The option grant will have a ten-year term.</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>On August 27 2020, the Board of Directors of the Company unanimously approved a resolution to increase the size of the Board of Directors from six to seven members and elected Ms. Cathy Coste, to serve as a director of the Company, effective September 3, 2020. The Board of Directors of the Company also voted that Ms. Coste will receive an option grant of 25,000 shares of our common stock which option grant vests one-quarter on August 27, 2021 and one-quarter on each yearly anniversary thereafter of the grant.&nbsp; The option grant will have a ten-year term.</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in; TEXT-INDENT:0.5in"><font style=FONT-SIZE:10pt>&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><b><font style=FONT-SIZE:10pt>Item 7.01 Regulation FD Disclosures.</font></b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><b><font style=FONT-SIZE:10pt>&nbsp;</font></b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>On August 31, 2020, Biomerica, Inc. (&#147;Biomerica&#148;) issued a press release announcing the aforementioned departure and appointment of certain officers and the appointment of a director.</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of, or otherwise regarded as filed under, the&nbsp;Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></p> <p class=MsoNormal style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>&nbsp;</font></p> <p class=MsoNormal style="TEXT-ALIGN:justify; MARGIN:0in"><b><font style=FONT-SIZE:10pt>Item 8.01 Other Events.</font></b></p> <p class=MsoNormal style="TEXT-ALIGN:justify; MARGIN:0in"><b><font style=FONT-SIZE:10pt>&nbsp;</font></b></p> <p class=MsoNormal style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt>On August 27, 2020, Biomerica, Inc. appointed Mr. Steve Sloan to serve as the CFO of the Company and Ms. Cathy Coste to the Board of Directors of the Company, both effective September 3, 2020.</font></p> <p class=MsoNormal style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt></font>&nbsp;</p> <p class=MsoNormal style="TEXT-ALIGN:justify; MARGIN:0in"><font style=FONT-SIZE:10pt></font>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt'> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; MARGIN:0in 0in 0pt'><b><font style=COLOR:black>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.25in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 12pt 0.5in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>(d) &nbsp; Exhibits. </font></p></p> <div align=center> <table width=99% bordercolor=transparent style="WIDTH:99.42%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=9% nowrap style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%' align=center><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">&nbsp;</font><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">Number</font></u></b></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">&nbsp;&nbsp;</font></p></td> <td width=89% nowrap style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.7pt; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">Description</font></u></b></p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%' align=center>99.1</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>Press Release issued August&nbsp;31, 2020.</p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:11.25pt 0in 0pt; LINE-HEIGHT:120%' align=center>2<b> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> <p /></b> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:11.25pt 0in 0pt; LINE-HEIGHT:120%' align=center><b>SIGNATURE</b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:7.5pt 0in 0pt; LINE-HEIGHT:120%; TEXT-INDENT:23pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 7pt 275pt; TEXT-INDENT:-23pt'>&nbsp;</p> <div align=center> <table width=600 bordercolor=transparent style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=T13></p></a></td> <td width=47% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black"><b>BIOMERICA, INC.</b></font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=T13><font style="FONT-SIZE:11pt; COLOR:black">Date:&nbsp; September 2, 2020</font></a></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">By:</font></p></td> <td width=47% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:47%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">&nbsp;/s/&nbsp;Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Chief Executive Officer</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>3</p></div></a></body>
<!-- EDGAR Validation Code: 7DD6756F -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head><title>Exhibit 99.1</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <p style="PADDING-LEFT:7px; MARGIN:0px">&nbsp;</p> <p style="PADDING-LEFT:7px; MARGIN:0px">&nbsp; <img width=726 height=123 style="HEIGHT:36px; WIDTH:162px" src=graphic1.jpg></p> <p style=MARGIN:0px><br></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:13.5pt; MARGIN-BOTTOM:0px; MARGIN-TOP:7px; COLOR:#002b3f; PADDING-LEFT:22px; PADDING-RIGHT:21px" align=center><strong>Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors.</strong></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; COLOR:#002b3f; PADDING-LEFT:8px; MARGIN:0px; PADDING-RIGHT:6px" align=justify><font face="Times New Roman">IRVINE, CA - (August 31, 2020) - Biomerica Inc. (NASDAQ: <font style=COLOR:#0070ba>BMRA</font>) today announced today the retirement of Janet Moore, the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s Chief Financial Officer. After many years of dedicated service, Ms. Moore has decided to retire and pursue personal interests. Ms. Moore will remain an employee of the Company during a transition period to ensure a smooth transition. Ms. Moore, who also serves as a member of the Board of Directors (the <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Board<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) and Corporate Secretary, will continue to serve as a member of the Board and as Corporate Secretary until the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s Annual Meeting on December 10, 2020. At that time, Ms. Moore will also be leaving the Board.</font></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; COLOR:#002b3f; PADDING-LEFT:8px; MARGIN:0px; PADDING-RIGHT:6px" align=justify><font face="Times New Roman">Biomerica also announced today the appointment of Steve Sloan as the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s new CFO, effective September 3, 2020. Mr. Sloan<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s background and experience includes thirteen years at General Electric with roles in internal audit, corporate finance and manufacturing finance. Most recently, Mr. Sloan spent ten years with medical device maker, Medtronic. At Medtronic, Mr. Sloan worked in four divisions, most recently serving as a divisional finance director.</font></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; COLOR:#002b3f; PADDING-LEFT:8px; MARGIN:0px; PADDING-RIGHT:6px" align=justify><font face="Times New Roman">Biomerica further announced that the Board has elected Cathy Coste as a new independent member of the Board. Cathy will join the Board effective September 3, 2020. Ms. Coste has also been elected by the Board to chair the Board<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s Audit Committee, and to be a member of the Nominating and Corporate Governance Committee. Cathy Coste is a Senior Partner at Deloitte and Touche, LLP, and is retiring in September 2020. She has spent thirty-two years in both corporate and professional services positions leading global finance, internal audit and operations teams. For the past six years, Cathy has served as Deloitte<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s Life Sciences Industry Executive Leader. Ms. Coste is known for her expertise in governance, audit, risk and controls, and compliance and has served over 50 companies in the life science, technology, and consumer industries.</font></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; COLOR:#002b3f; PADDING-LEFT:8px; MARGIN:0px; PADDING-RIGHT:6px" align=justify><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font><font face="Times New Roman">I personally want to thank Janet for being a trusted advisor and leader throughout her career at the Company in serving as CFO, Board Member and Secretary. At the same time, I<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>m excited to have Steve Sloan join our executive management team as CFO. Steve brings great knowledge, experience and energy to the position and I am confident he will play a key role in helping us achieve our goals of building Biomerica. Finally, on behalf &nbsp;of the Board, I welcome Cathy Coste and I am looking forward to working with her, especially given her experience in the life sciences industry.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font></font></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; PADDING-LEFT:8px; MARGIN:0px; PADDING-RIGHT:6px" align=justify><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font><font face="Times New Roman">Biomerica has a bold vision of developing a diagnostic guided therapy with its InFoods product. I<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>m honored to assume the role of Audit Committee Chairman and look forward to an exciting new fiscal year and beyond for Biomerica.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> said Cathy Coste.</font></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; COLOR:#002b3f; PADDING-LEFT:8px; MARGIN:0px; PADDING-RIGHT:7px" align=justify><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font><font face="Times New Roman">It has been my pleasure and privilege to serve as Biomerica<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s CFO. The Company has many talented, dedicated employees and innovative products which, I believe, will ensure the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s continued success.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> said Janet Moore.</font></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:10.5pt; COLOR:#002b3f; PADDING-LEFT:8px; MARGIN:0px" align=justify><strong>About Biomerica (NASDAQ: <font style=COLOR:#0070ba>BMRA</font>)</strong></p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:0px; FONT-FAMILY:Calibri,Times New Roman; MARGIN-TOP:0px; COLOR:#002b3f; PADDING-LEFT:8px; PADDING-RIGHT:6px" align=justify><font face="Times New Roman">Biomerica, Inc. (<font style=COLOR:#0070ba>www.biomerica.com</font>) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:4px" align=justify><br><br></p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <br> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:10.5pt; COLOR:#002b3f; PADDING-LEFT:6px; MARGIN:0px" align=justify><strong>About InFoods&#174;</strong></p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:0px; FONT-FAMILY:Calibri,Times New Roman; MARGIN-TOP:0px; COLOR:#002b3f; PADDING-LEFT:6px; PADDING-RIGHT:6px" align=justify><font face="Times New Roman">The Biomerica InFoods&#174; IBS product is designed to allow physicians to identify patient specific foods (e.g. eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient-specific, guided dietary regimen to improve Irritable Bowel Syndrome (<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>IBS<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product is expected to be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods&#174; diagnostic products. Since the InFoods&#174; product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.</font></p> <p style=MARGIN:0px><br></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; COLOR:#002b3f; PADDING-LEFT:6px; MARGIN:0px; PADDING-RIGHT:6px" align=justify><font face="Times New Roman">The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COVID-19 test, FDA clearance, EUA clearance, the rapidity of testing results, uniqueness of a product, pricing of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s test kits, demand for international orders, availability of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COVID-19 test kits, and patent protection on the test technology. Such forward- looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COVID-19 test; regulatory approvals necessary prior to commercialization of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COVID-19 test; availability of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COVID-19 test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our COVID-19 test; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s ability to obtain patent protection on any aspects of its rapid test technology. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</font></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11.5pt; MARGIN-BOTTOM:0px; MARGIN-TOP:12px; PADDING-LEFT:6px" align=justify><strong>CONTACT INFORMATION</strong></p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:0px; FONT-FAMILY:Calibri,Times New Roman; MARGIN-TOP:4px; COLOR:#002b3f; PADDING-LEFT:6px; PADDING-RIGHT:444px"><font face="Times New Roman">Company Spokesperson 949-645-2111</font></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Calibri,Times New Roman; COLOR:#0070ba; PADDING-LEFT:6px; MARGIN:0px; LINE-HEIGHT:12.7pt"><font face="Times New Roman">www.biomerica.com</font></p> <p style="MARGIN:0px; LINE-HEIGHT:12.7pt"><br></p></body>
<!-- EDGAR Validation Code: 18AB2259 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graphic1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graphic1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ![ M<# 2(  A$! Q$!_\0
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MD?33(/RJ3_A7F@?] V'\J^$_UKI_\^S[G_56K_S\/R!O9?$NC?\ 'Q)?Q?\
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MVFL,OW=,_(9NO_$9ZM^SS\2M6T?XF:5Y]_/+;22?O/,DK]6-/O(]2L8KA/\
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M^Z:6DKC/0/RR_; OX[KXF7$"?ZSS*\%6W+-C/%?I3\3?V.=,^(/BBXU:>?\
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MG+<A7UG,*G/,Y666263S)/WM1^77T3X/_8[\7:Q)&]Y:BUC^M>]^#?V&-$M
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MG[EL*V;?X!^!(_NZ%C_M\N/_ (Y5RW^#?A"'[FDLO_;W/_\ %TN5H%4R>/\
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LJ:BBH,!*6BB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
